Benzinga | Aug 10, 2020 04:20PM EDT

Akebia Therapeutics Q2 EPS $(0.44) Beats $(0.50) Estimate, Sales $90.14M Beat $74.18M Estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.50) by 12 percent. This is a 76 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $90.14 million which beat the analyst consensus estimate of $74.18 million by 21.52 percent. This is a 10.58 percent decrease over sales of $100.80 million the same period last year.